

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

FURTHER SHARE BUY-BACK PLAN OF UP TO HK\$5 BILLION

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, collectively the “**Group**”) on a voluntary basis.

As disclosed in the 2024 Interim Results announcement of the Company dated 21 August 2024, the Company has completed share buy-backs for an aggregate of HK\$387 million in the first half of 2024. The board of directors of the Company (the “**Board**”) has approved a further share buy-back plan of up to HK\$1 billion, out of which, approximately HK\$773 million have been utilised to buy-back a total of 163,860,000 shares of the Company up to the date of this announcement. The shares bought back will be cancelled.

The Board has further resolved that, subject to market conditions, the Company will buy-back shares on-market for an aggregate of up to HK\$5 billion (in addition to the aforesaid amount of HK\$1 billion) within a period of 24 months from the date of this announcement at such times and intervals as may be decided by the Board from time to time. The Company will finance the share buy-backs from its available cash reserves. The shares bought back will be cancelled.

The share buy-back plans will be conducted pursuant to and subject to the limits under the relevant share buy-back mandate granted or to be granted to the directors by the shareholders of the Company at its annual general meetings (including the annual general meeting held on 28 May 2024), and will be implemented in compliance with the Listing Rules and other applicable laws, rules, regulations and codes. It is expected that the implementation of the share buy-back plans will not give rise to any general offer obligation for the Company or any of its shareholders under the Codes on Takeovers and Mergers and Share Buy-backs.

The Board has full confidence in the Group's business development and outlook, and considers that the current share price of the Company is below its actual value. The implementation of the share buy-back plans aims to demonstrate the Company's confidence in its business prospects and enhance shareholders' returns. The Board believes that it is in the best interests of the Company and its shareholders as a whole to implement the share buy-back plans.

The implementation of the share buy-back plans by the Company is subject to market conditions and will be at the absolute discretion of the Board. There is no assurance (implied or given) as to the timing, quantity or price of the share buy-backs. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 19 September 2024

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. JIANG Hao, Dr. YAO Bing and Mr. CAI Xin as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.